UOC
UBS O'Connor Portfolio holdings
AUM
$1.93B
1-Year Return
38.75%
This Quarter Return
+9.42%
1 Year Return
+38.75%
3 Year Return
+182.42%
5 Year Return
+480.25%
10 Year Return
+1,573.29%
AUM
$1.93B
AUM Growth
-$1.38B
(-42%)
Cap. Flow
-$1.51B
Cap. Flow
% of AUM
-78.18%
Top 10 Holdings %
Top 10 Hldgs %
53.92%
Holding
430
New
110
Increased
47
Reduced
78
Closed
95
Top Buys
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$218M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
$63.3M |
| 3 |
CenterPoint Energy
CNP
|
$19.3M |
| 4 |
ESGR
Enstar Group
ESGR
|
$17M |
| 5 |
Duke Energy
DUK
|
$17M |
Top Sells
| 1 |
DFS
Discover Financial Services
DFS
|
$408M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$408M |
| 3 |
HES
Hess
HES
|
$257M |
| 4 |
BECN
Beacon Roofing Supply, Inc.
BECN
|
$195M |
| 5 |
BERY
Berry Global Group, Inc.
BERY
|
$137M |
Sector Composition
| 1 | Technology | 21.57% |
| 2 | Healthcare | 20.43% |
| 3 | Energy | 18.73% |
| 4 | Financials | 8.84% |
| 5 | Industrials | 7.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
201
Levi Strauss
LEVI
$8.92B
| $925K | 0.05% |
+50,000
| New | +$925K |
|
202
Praxis Precision Medicines
PRAX
$970M
| $921K | 0.05% |
21,892
-4,901
| -18% | -$206K |
|
203
KE Holdings
BEKE
$21.9B
| $919K | 0.05% |
+51,814
| New | +$919K |
|
|
RAAQ
204
Real Asset Acquisition Corp. Class A Ordinary Share
RAAQ
$233M
| $911K | 0.05% |
+89,645
| New | +$911K |
|
205
Scholar Rock
SRRK
$3.12B
| $901K | 0.05% |
25,426
-2,191
| -8% | -$77.6K |
|
206
KalVista Pharmaceuticals
KALV
$765M
| $898K | 0.05% |
79,460
-90,232
| -53% | -$1.02M |
|
207
GE Vernova
GEV
$163B
| $889K | 0.05% |
+1,680
| New | +$889K |
|
208
Larimar Therapeutics
LRMR
$331M
| $888K | 0.05% |
307,198
+127,171
| +71% | +$368K |
|
209
uniQure
QURE
$973M
| $885K | 0.05% |
63,475
-51,414
| -45% | -$717K |
|
210
Axogen
AXGN
$709M
| $884K | 0.05% |
81,429
-5,999
| -7% | -$65.1K |
|
211
Merus
MRUS
$5.01B
| $879K | 0.05% |
16,704
-7,528
| -31% | -$396K |
|
212
Soleno Therapeutics
SLNO
$3.7B
| $868K | 0.04% |
10,362
-6,660
| -39% | -$558K |
|
213
Adaptive Biotechnologies
ADPT
$1.98B
| $856K | 0.04% |
73,441
-114,348
| -61% | -$1.33M |
|
214
AnaptysBio
ANAB
$590M
| $855K | 0.04% |
38,528
-8,523
| -18% | -$189K |
|
215
Syndax Pharmaceuticals
SNDX
$1.39B
| $847K | 0.04% |
90,441
+31,003
| +52% | +$290K |
|
216
Protagonist Therapeutics
PTGX
$3.71B
| $803K | 0.04% |
14,523
+1,183
| +9% | +$65.4K |
|
217
Orthofix Medical
OFIX
$581M
| $753K | 0.04% |
67,518
-21,541
| -24% | -$240K |
|
|
SPKL
218
Spark I Acquisition Corp
SPKL
$95.1M
| $728K | 0.04% |
66,832
| – | – |
|
219
Edgewise Therapeutics
EWTX
$1.54B
| $725K | 0.04% |
55,292
+15,278
| +38% | +$200K |
|
220
PTC Therapeutics
PTCT
$4.61B
| $711K | 0.04% |
14,548
-8,805
| -38% | -$430K |
|
221
Day One Biopharmaceuticals
DAWN
$759M
| $697K | 0.04% |
107,249
-6,001
| -5% | -$39K |
|
222
TG Therapeutics
TGTX
$5.06B
| $684K | 0.04% |
+19,000
| New | +$684K |
|
223
CG Oncology
CGON
$2.36B
| $676K | 0.03% |
+26,000
| New | +$676K |
|
224
Axsome Therapeutics
AXSM
$6.21B
| $668K | 0.03% |
+6,400
| New | +$668K |
|
225
Skillsoft
SKIL
$131M
| $666K | 0.03% |
41,692
| – | – |
|